Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA166593, U54 CA196519)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 10 October 2019
Revised: 25 March 2020
Accepted: 1 May 2020
First Online: 22 May 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Not applicable.
: The authors declare no competing interests.
: L.Q.L. is supported by funding from the National Cancer Institute of the National Institutes of Health (grant number R01 CA166593 and U54 CA196519), the US Department of Defense, the Neurofibromatosis Therapeutic Acceleration Program, the NF1 Research Consortium Fund, and the Giorgio Foundation. J.P.B. and C.P.L. are recipient of the Young Investigator Award from the Children’s Tumor Foundation. J.P.B. is also an Early Investigator Research Award from the US Department of Defense. C.P.L. is also a recipient of the Career Development Award from Dermatology Foundation. L.Q.L. holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund and the Thomas L. Shields, M.D. Professorship in Dermatology.